Mersana Therapeutics, Inc. (MRSN) Financials
MRSN Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 226.1 million | 189.2 million |
2023-09-30 | 262.9 million | 210.7 million |
2023-06-30 | 311.0 million | 221.2 million |
2023-03-31 | 296.2 million | 231.9 million |
MRSN Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -34.5 million | 4.1 million |
2023-09-30 | -46.6 million | 4.0 million |
2023-06-30 | -62.2 million | 6.6 million |
2023-03-31 | -29.9 million | 6.4 million |
MRSN Net Income
No data available :(
MRSN Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 209.1 million | - | 8.4 million |
2023-09-30 | 241.0 million | - | 9.2 million |
2023-06-30 | 286.6 million | 25.1 million | 10.0 million |
2023-03-31 | 273.9 million | 25.0 million | 10.7 million |
MRSN Shares Outstanding
MRSN Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 386000 | 21.5 million | 10.1 million | 447000 |
2023-09-30 | 472000 | 30.5 million | 12.9 million | - |
2023-06-30 | 399000 | 49.0 million | 18.2 million | - |
2023-03-31 | 911000 | 47.3 million | 18.3 million | - |
MRSN Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 10.7 million | 447000 |
2023-09-30 | 7.7 million | 427000 |
2023-06-30 | 10.7 million | 324000 |
2023-03-31 | 7.8 million | 319000 |
MRSN
Price: $3.40
52 week price:
Earnings Per Share: -1.48 USD
P/E Ratio: -2.20
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 915100
Ebitda: -7.8 millionMarket Capitalization: 462.2 million